Showing results for "Alterity Therapeutics"
industries
Verve Falls as Gene-Editing Trial Paused on Safety IssuesVerve Therapeutics Inc. shares tumbled after it cited safety concerns for pausing enrollment in a study of its gene-editing treatment for people with high cholesterol, delivering a setback to the promising new field of medicine.April 2, 2024
markets
LSD, Ecstasy Lure Traders Betting on ‘Psychedelic Renaissance’For years, investors that poured money into psychedelic stocks have wagered that their breakout moment — and the eye-watering returns that would quickly follow — were just around the corner. And year after year it’s been, by-and-large, a losing bet.March 28, 2024
industries
AbbVie CEO Who Grew Company Through Big M&A Deals Set to RetireAbbVie Inc.’s Chief Executive Officer Richard A. Gonzalez will retire after a colorful tenure that included the multibillion takeover of Botox-maker Allergan as he raced to wean the company off of its reliance on blockbuster Humira.February 20, 2024
industries
What Is Crispr, the DNA Editing Tool Behind the New Sickle Cell TherapyHumans have been manipulating genetics since early civilizations realized that certain traits of crops, animals and people themselves were hereditary. The modern-day mapping of all human genes raised the prospect of learning precisely which genes control which traits and then directly altering their DNA codes. After years of hit-and-miss efforts, a gene-editing system called Crispr that’s cheap, effective and easy to use promises to change our relationship with genetics — for better, worse or boDecember 14, 2023
industries
First Crispr Therapy Gets FDA Nod for Sickle Cell DiseaseThe US Food and Drug Administration approved the first gene editing therapy using Crispr technology on Friday, a collaboration between Vertex Pharmaceuticals Inc. and Crispr Therapeutics AG for treating sickle cell disease.December 8, 2023
industries
FDA Staff Raises Concerns Over Crispr Therapy Safety DataThe Food and Drug Administration’s staff raised concerns about safety data on a potential gene-editing treatment for sickle cell disease, ahead of a closely watched meeting where scientific experts will weigh the first therapy using Crispr technology.October 27, 2023